Gene Therapy Deal Aims to Speed Blindness Cure

Genezen and Atsena join forces to manufacture AAV gene therapies for inherited retinal diseases as ATSN-201 moves toward a planned 2028 regulatory filing

10 Mar 2026

Atsena Therapeutics and Genezen have entered a manufacturing partnership aimed at advancing gene therapies for inherited retinal diseases, conditions that gradually impair vision and often lack effective treatments. Announced on Jan. 20, 2026, the agreement designates Genezen as the manufacturer for both clinical and commercial supply of Atsena’s adeno-associated virus (AAV) gene therapy programs as they move toward later-stage trials and potential regulatory review.

The collaboration brings together a clinical-stage developer focused on ocular gene therapies and a contract development and manufacturing organization with experience in viral vector production. Under the arrangement, Genezen will manufacture therapies using Atsena’s existing production platform. According to the companies, maintaining Atsena’s established process is intended to reduce the risk associated with technology transfer while keeping manufacturing timelines aligned with the company’s regulatory plans.

The partnership is closely tied to ATSN-201, Atsena’s lead program for X-linked retinoschisis, a childhood-onset genetic disorder that leads to progressive loss of central vision. The therapy is currently being evaluated in the pivotal LIGHTHOUSE study. Enrollment in the trial’s pivotal Part C cohort is expected to begin in the first quarter of 2026. Atsena has said it is targeting a Biologics License Application filing in early 2028 if development proceeds as planned.

Company officials said the agreement reflects preparation for later stages of development, when reliable manufacturing capacity becomes critical. Steve Favaloro, Genezen’s chief executive, said the company intends to support Atsena’s programs as they approach pivotal readiness. Atsena’s manufacturing leadership also cited Genezen’s experience in viral vector production as a key factor in selecting the partner.

The deal also underscores a broader trend in gene therapy development, in which companies are securing large-scale manufacturing partners earlier in the clinical process. Analysts have said that earlier planning may help avoid supply constraints that complicated some earlier gene therapy launches. Atsena’s pipeline extends beyond X-linked retinoschisis to include programs targeting Leber congenital amaurosis and Usher syndrome, suggesting the partnership could support multiple therapies as development progresses in the years ahead.